Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 14Active not recruiting 13Recruiting 10Terminated 4Not yet recruiting 3Withdrawn 1Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1CNS 1

Conditions

Pancreatic Neoplasms 1

Interventions

Gemcitabine 7Specimen Handling 6Oxaliplatin 5Irinotecan 5S 1 (combination) 4Magnetic Resonance Spectroscopy 4Leucovorin 4Fluorouracil 4Capecitabine 4Biopsy 4Bevacizumab 4Radiotherapy 3Nivolumab 3Immunotherapy 3Drug Therapy 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3trifluridine tipiracil drug combination 2titanium silicide 2spartalizumab 2lenvatinib 2aldesleukin 2Taxes 2Surgical Procedures, Operative 2Radiosurgery 2Photochemotherapy 2Interleukin-2 2Endoscopic Mucosal Resection 2Cyclophosphamide 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Immunoglobulin G × Gastrointestinal × Clear all
NCT05411094 2026-05-29

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Suspended
18 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡